Taking Stock
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Watch Shield Diagnostic, the health care group. Tomorrow an investment lunch, hosted by stockbroker Sutherlands, is due to be held in Edinburgh. And the company should hear this week what the American Food and Drug Administration thinks about its key product, its AFT heart attack test. The shares rose 25p to 680p; they have had a volatile year, moving between 805p and 110.5p.
Petra Diamonds, which last month raised pounds 4.5m through a placing, has taken on two more concessions in Angola. Michael Long, a mining analyst for 30 years, has produced, under the banner of stockbroker IA Pritchard, a detailed study. He believes Petra should be in profit by 1999 with up to pounds 1.8m possible. The shares, up 3p to 106.5p, are, he says, a buy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments